RBM3 and metastatic neoplasm: Along this line, the observation that the expression of RBM3 was significantly higher in lymph node metastases compared to primary tumors, in particular in PB-type tumors, is highly relevant, as it is the metastatic tumor component that will have the greatest impact on clinical outcome.